ホーム>>Signaling Pathways>> GPCR/G protein>> EBI2/GPR183>>SAE-14

SAE-14 (Synonyms: GPR183 antagonist-1)

カタログ番号GC65986

SAE-14 (化合物 SAE-14) は、IC50 値が 28.5 nM の強力な特異的 GPR183 アンタゴニストであり、&7#945 に拮抗することができます。 GPR183 アンタゴニスト 1 は、マウスのアロディニアを逆転させることができます。

Products are for research use only. Not for human use. We do not sell to patients.

SAE-14 化学構造

Cas No.: 1241280-25-0

サイズ 価格 在庫数 個数
10mg
$387.00
在庫あり
25mg
$729.00
在庫あり
50mg
$1,080.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

IC50: 28.5 nM (GPR183)[1]

SAE-14 (compound SAE-14) is a potent, specific GPR183 antagonist with an IC50 value of 28.5 nM, can antagonize 7α, 25-OHC-induced calcium mobilization with IC50 value below 50 nM in HL-60 cells. GPR183 antagonist-1 can reverse allodynia in mice[1].

SAE-14 (compound SAE-14) can able to antagonize 7α, 25-OHC-induced calcium mobilization with an IC50 value below 50 nM[1].

Cell Viability Assay[1]

Cell Line: The human leukemia (HL)-60 cells
Concentration: 5×of the antagonist
Incubation Time: 15 min
Result: Had GPR183-specific (IC50: 28.5nM) and abolished 7a, 25-OHC-induced calcium mobilization in the HL-60 cells.

SAE-14 (compound SAE-14) (i.th.; 2.9 µM; once) can reverse nerve injury-induced allodynia in mice[1].

Animal Model: Male and female ICR mice[1]
Dosage: 2.9 µM
Administration: intrathecal (i.th.) injections; 2.9 µM; once
Result: Reversed CCI-induced mechanical allodynia in a time-dependent manner.

レビュー

Review for SAE-14

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SAE-14

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.